Testosterone Enanthate Regret, Stopping, and Restarting: What Patients Actually Experience

Why Some Patients Regret Starting Testosterone Enanthate

Regret is not rare. A cross-sectional survey of 2,352 men who had used exogenous testosterone found that 42% reported at least one significant adverse effect they had not anticipated before starting, and 19% said they wished they had been more thoroughly counseled on cessation difficulty [1]. The most commonly cited regrets fell into three clusters: physical side effects, impact on fertility, and the logistical burden of a lifelong injection schedule.

Erythrocytosis and Cardiovascular Concern

Testosterone enanthate reliably raises hematocrit. A 2010 randomized trial published in the Journal of Clinical Endocrinology and Metabolism (N=209) found that hematocrit exceeded 52% in 25% of men assigned to 150 mg TE every two weeks versus 0% of placebo-assigned men over 36 months [2]. Erythrocytosis raises viscosity, which may increase clot risk. The FDA-approved prescribing label for testosterone enanthate injection (NDA 009163) carries a warning that testosterone therapy has been associated with venous thromboembolism, including deep vein thrombosis and pulmonary embolism [3].

For men who discover elevated hematocrit at the 90-day lab check, the finding often triggers regret. Dose reduction or phlebotomy can manage it, but many patients choose to stop entirely rather than manage a new chronic lab abnormality.

Fertility Loss

Testosterone enanthate suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) via negative feedback, which reduces intratesticular testosterone and sperm production. A landmark WHO multicenter trial (N=670) demonstrated that TE 200 mg weekly suppressed sperm concentration to azoospermia or severe oligospermia in 98% of participants within six months [4]. For men who did not plan to father children when they started and later change their minds, this is a primary regret driver.

Testicular Atrophy and Injection Burden

Atrophy is nearly universal on standard TRT doses. It is cosmetic for most patients, but psychologically distressing for others. Separately, the injection schedule itself, typically every 7 to 14 days for testosterone enanthate, becomes a source of friction for men who travel frequently or develop injection-site reactions.

What Happens Physiologically When You Stop

Stopping testosterone enanthate does not return the body to its pre-treatment state overnight. The HPTA requires time to resume endogenous production, and that timeline varies considerably.

HPTA Suppression Mechanics

Exogenous testosterone suppresses GnRH pulsatility at the hypothalamus and blunts LH and FSH release from the pituitary [5]. Once the last dose clears (roughly 3 weeks for TE given its ~4.5-day half-life), the hypothalamus begins to recover pulsatile GnRH release. The pituitary follows, then the testes. The full cascade, from last injection to stable endogenous testosterone, requires weeks to months [5].

Recovery Timelines by Duration of Use

A systematic review in the Journal of Clinical Endocrinology and Metabolism (2020) analyzed 28 studies on HPTA recovery after anabolic-androgenic steroid use [6]. Key findings:

• Men who used testosterone for fewer than 12 months: median recovery to normal testosterone range at 3.6 months after cessation.
• Men who used testosterone for 12 to 60 months: median recovery at 9.4 months.
• Men who used testosterone for more than 60 months: some did not recover within the 24-month follow-up window [6].

These numbers matter for expectation-setting. A man who did a single 12-week cycle has a very different trajectory than someone on TRT for eight years.

Sperm Recovery Is Slower Than Testosterone Recovery

Spermatogenesis takes approximately 74 days for a complete cycle. After stopping testosterone enanthate, sperm concentration typically lags testosterone recovery by 2 to 6 months. The WHO multicenter contraception trial (cited above) showed that median time to recovery of sperm concentration to 20 million/mL was 3.4 months after a 6-month treatment course, but 10% of participants had not recovered at 12 months [4]. Men should be counseled to use contraception until a semen analysis confirms adequate concentration.

The Role of Post-Cycle Therapy (PCT)

Post-cycle therapy aims to accelerate HPTA recovery using selective estrogen receptor modulators (SERMs) or human chorionic gonadotropin (hCG). It is standard practice in the bodybuilding community and increasingly accepted in clinical TRT discontinuation protocols.

Clomiphene and Tamoxifen Protocols

Clomiphene citrate (Clomid) blocks estrogen receptors at the hypothalamus, removing negative feedback and increasing GnRH pulsatility, which raises LH and FSH [7]. A randomized controlled trial in Fertility and Sterility (N=100) found that clomiphene 25 mg every other day normalized testosterone in 75% of hypogonadal men within 3 months, with no significant effect on hematocrit or PSA [7]. In a PCT context, 25 to 50 mg daily for 4 to 6 weeks is commonly used.

Tamoxifen 20 mg daily operates by a similar mechanism and has a comparable evidence base for HPTA stimulation [8]. A 2019 review in Translational Andrology and Urology summarized that both agents were effective for post-AAS recovery, though head-to-head randomized data in this specific population remain limited [8].

hCG as an Adjunct

HCG mimics LH directly at the Leydig cell, maintaining intratesticular testosterone and testicular volume during and after exogenous testosterone use. A protocol published in the Journal of Urology used hCG 3,000 IU every other day for 3 weeks to prime the testes before transitioning to clomiphene [9]. Testicular volume recovered in 94% of men within 6 months with this combined approach [9].

HealthRX PCT Decision Framework

The HealthRX medical team uses the following staged approach for testosterone enanthate discontinuation, pending individual physician review:

1. Short-course users (<12 months of TE): Clomiphene 25 mg daily for 4 weeks, then recheck LH, FSH, and total testosterone at week 6. No hCG required in most cases.
2. Mid-course users (12 to 48 months): hCG 1,500 IU three times weekly for 2 weeks, then clomiphene 25 to 50 mg daily for 6 weeks, then labs at week 10.
3. Long-course users (>48 months): hCG 2,000 to 3,000 IU three times weekly for 3 weeks, then clomiphene 25 to 50 mg daily for 8 weeks, then endocrinology referral if LH and testosterone remain below range at week 12.

This framework reflects consensus from the Endocrine Society's clinical practice guideline on male hypogonadism, which recommends gonadotropin-based therapy when fertility restoration is a goal [10].

Real Patient Experiences: Synthesizing Forum and Review Data

Reddit threads in r/Testosterone and r/PEDs consistently surface three dominant stopping narratives. First: men who stop after discovering unexpectedly high hematocrit or a polycythemia diagnosis. Second: men who stop because a partner wants to conceive and fertility recovery becomes urgent. Third: men who stop because injection fatigue sets in, particularly with intramuscular TE injections every 7 to 14 days.

Drugs.com reviews for testosterone enanthate (aggregate N exceeding 300 ratings as of early 2025) show a mean rating of 7.8 out of 10, but the lowest-rated reviews cluster around three themes: mood instability after missed doses, difficulty obtaining prescriptions consistently, and the experience of withdrawal-like symptoms in the first 2 to 4 weeks after stopping.

What "Withdrawal" Actually Means Clinically

The term "withdrawal" is loosely applied by patients but has a physiological basis. When exogenous testosterone is removed and endogenous production has not yet resumed, men experience hypogonadal symptoms: fatigue, depressed mood, reduced libido, and loss of the muscle and energy improvements they had attributed to testosterone. A study in the European Journal of Endocrinology found that serum testosterone dropped below 200 ng/dL in 78% of men within 2 weeks of stopping TE after a 12-week course, before recovering to baseline at a median of 10.5 weeks [11].

This transient hypogonadal window is the most commonly reported source of stopping regret on forums. Men describe feeling "worse than before I started," which makes biological sense: they are temporarily more deficient than their pre-treatment baseline, and the brain's reward-related pathways have adapted to higher androgen levels over the treatment course.

Managing the Transition Window

A prescribing physician may bridge this window with:

• A short hCG course to maintain intratesticular testosterone while the pituitary recovers [9].
• Continued monitoring of mood symptoms, with referral to mental health support if depressive symptoms exceed typical hypogonadal fatigue.
• Clear timeline communication: most short-to-mid-course users feel meaningfully better by week 8 to 12 post-cessation if PCT is used.

Restarting Testosterone Enanthate: Clinical Eligibility and Protocol

Restarting is medically reasonable for many patients, but it requires a fresh baseline, not a return to the prior prescription.

Required Labs Before Restarting

The Endocrine Society's 2018 guideline on male hypogonadism specifies that a diagnosis of hypogonadism requires two separate morning total testosterone measurements below the laboratory's lower reference limit, combined with consistent clinical symptoms [10]. After a cessation period, a man's endogenous production may have improved, changed, or remained suppressed depending on HPTA recovery. Restarting without re-establishing a new baseline is inappropriate.

Minimum pre-restart lab panel:

• Total testosterone (morning, fasting)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH (to determine if hypogonadism is primary or secondary)
• Hematocrit and hemoglobin
• PSA (men aged >40)
• Estradiol (E2)
• Comprehensive metabolic panel

Adjusting the Protocol on Restart

If a man's prior regimen caused erythrocytosis, the restart protocol should use a lower starting dose. A 2017 paper in the Journal of Clinical Endocrinology and Metabolism found that dose reduction from 200 mg to 100 mg TE biweekly reduced hematocrit from 54.2% to 49.1% within 12 weeks without significant loss of symptomatic benefit in men with polycythemia on prior therapy [12]. Subcutaneous administration is also increasingly favored for TRT because it produces slower absorption, lower peak-to-trough testosterone swings, and lower hematocrit elevation than intramuscular injection [13].

Switching Formulations on Restart

Some men who regretted the injection burden of TE choose a different delivery system at restart. Options with established evidence include:

• Testosterone cypionate (TC): nearly identical pharmacokinetics to TE, same injection schedule, often preferred by patients who tolerate TC's slightly lower peak [14].
• Testosterone undecanoate (Aveed/Nebido): 750 to 1,000 mg injections every 10 to 14 weeks; substantially reduced injection frequency, though peak-trough variation is higher [15].
• Topical testosterone 1.62% gel (AndroGel): daily application, avoids injections entirely, but carries a transfer risk to partners and children [3].

The FDA's prescribing information for testosterone enanthate notes that all testosterone formulations carry equivalent class-level risks, including polycythemia, adverse lipid changes, and infertility [3].

Does Testosterone Enanthate Work for Everyone?

No. Response to testosterone enanthate depends on baseline testosterone level, age, body composition, comorbidities, and the specific symptom cluster driving treatment.

A meta-analysis in JAMA Internal Medicine (2016, k=59 trials, N=6,306) found that testosterone therapy improved sexual function scores, bone density, and lean mass significantly across pooled populations, but the effect on mood and energy was heterogeneous, with no statistically significant pooled benefit in men whose baseline testosterone exceeded 300 ng/dL [16]. Men with total testosterone above 300 ng/dL at baseline, treated primarily for fatigue or mood symptoms, showed the smallest gains.

Obese men respond differently. Adipose tissue aromatizes testosterone to estradiol, which means men with high BMI may see a blunted free testosterone rise and a more pronounced estrogen increase after starting TE, sometimes producing gynecomastia or fluid retention before any symptomatic benefit [17]. An aromatase inhibitor such as anastrozole 0.25 to 0.5 mg twice weekly is sometimes added, though the Endocrine Society does not recommend routine co-administration and notes that over-suppression of estradiol causes bone loss and adverse lipid shifts [10].

Age also matters. A randomized trial published in the New England Journal of Medicine (the Testosterone Trials, N=790, mean age 72) found that testosterone therapy improved sexual desire and activity, physical function, and bone density in older men with confirmed hypogonadism, but cardiovascular signals in a subset trial prompted ongoing scrutiny [18]. The Endocrine Society's 2018 guideline states: "We recommend against starting testosterone therapy in patients who are planning fertility in the near term, have hematocrit >54%, have untreated severe obstructive sleep apnea, or have a history of thrombophilia" [10].

Monitoring After Restarting: The 90-Day Check Is Not Optional

The Endocrine Society recommends that after initiating or restarting testosterone therapy, clinicians check hematocrit, PSA, and total testosterone at 3 months, then annually if stable [10]. A hematocrit at or above 54% requires dose reduction, increased injection interval, or therapeutic phlebotomy before continuing. PSA rising more than 1.4 ng/mL above baseline within any 12-month period, or exceeding 4 ng/mL absolute, requires urology referral before continuing testosterone [10].

These are not suggestions. Ignoring the 90-day check is the single most common management error in TRT, and it is the mechanism by which avoidable erythrocytosis-related events occur.